UK Blood Group Typing Market Analysis

UK Blood Group Typing Market Executive Summary

The UK Blood Group Typing Market is at around $89.44 Mn in 2023 and is projected to reach $150.33 Mn in 2030, exhibiting a CAGR of 7.70% during the forecast period.

Blood typing is a method to tell what type of blood the individual has. Blood typing is done so they can safely donate or receive a blood transfusion. Blood group determination helps understand a person’s blood group and determine the presence of Rh factor in RBCs. ABO and Rh blood group typing procedures are used to determine an individual’s blood type, which is essential for safe blood transfusions. The presence or lack of specific proteins on RBCs known as antigens shape a person’s blood type, which is inherited from their parents. Four main blood types are distinguished using the ABO blood typing system: Type A, Type B, Type AB, and Type O.

Blood typing is important for several reasons like, safe blood transfusions and matching donor and recipient blood types prevent potentially life-threatening transfusion reactions. Pregnant women must know their blood type, especially the Rh factor. This helps prevent complications like hemolytic disease in the newborn. Blood typing can provide information for genetic studies and inheritance patterns. It also plays a key factor in organ transplant matching to reduce the risk of organ rejection.

The increase in donations over the years signifies that the number of blood group typing procedures has also increased. Furthermore, the increasing prevalence of diseases associated with blood, such as sickle cell anemia, thalassemia, lymphoma, leukemia, and haemophilia, is also supporting the growth of blood group typing. Sickle cell anemia affects approximately 15,000 people in UK. The market therefore is driven by significant factors like the rise in the number of surgical procedures, technological advancements, and increasing prenatal testing. However, rising costs, limited accessibility, and transfusion related infections restrict the growth of the market.

The prominent companies for blood group typing include Grifols, S.A., and Bio-Rad Laboratories. Thermo Fisher Scientific Inc., Becton, Dickinson and Company, and Quotient Limited are also significant contributors to UK Blood Group Typing Market.

Market Dynamics

Market Growth Drivers

Rising Number of Surgical Procedures: As the UK's healthcare system continues to expand and improve, the frequency of surgical procedures is increasing. There is an increase in road accidents and other traumatic incidents that require immediate surgical intervention and blood transfusions.

Technological Advancements: Innovations in blood typing technologies, such as automated systems and rapid testing devices, are making blood typing more efficient and accessible. This technological progress is expected to facilitate market growth as it improves the accuracy and speed of blood typing.

Prenatal Testing: Blood typing plays a vital role in prenatal testing to identify potential Rh factor incompatibilities between mother and baby. All pregnant women in UK are routinely tested for their blood group and Rh type (RhD positive or RhD negative) during the first trimester and again at 28 weeks gestation.

Market Restraints

Cost Constraint: Implementing advanced blood typing technologies, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), can be financially burdensome, especially for smaller healthcare facilities and blood banks. The high costs associated with purchasing and maintaining sophisticated equipment limits accessibility to these technologies, particularly in resource-constrained settings.

Limited Access: Access to advanced blood typing technologies is limited in rural or underserved regions of UK, potentially hindering the provision of accurate blood typing services. This disparity can lead to delays in treatment and complications during blood transfusions, affecting overall patient outcomes.

Transfusion- Transmitted Infection: Despite stringent testing, there's always a slight risk of TTIs through blood transfusions. Researchers have identified new infectious diseases transmissible through blood, additional tests are incorporated into the blood typing process. This increases the complexity of the procedure and potentially lengthens processing times.

Regulatory Landscape and Reimbursement Scenario

Medicines and Healthcare Products Regulatory Agency (MHRA) oversees the regulation of in-vitro diagnostics and blood components for transfusion, ensuring they meet applicable safety and quality standards. It is responsible for the regulation of medical devices and promotes international standardization of biological medicines, including blood products. United Kingdom Accreditation Service (UKAS) is the national accreditation body that assesses laboratories against recognized standards, primarily ISO 15189, which applies to medical laboratories. The Blood Safety and Quality Regulations, 2005 is the core legislation that sets the standards for blood collection, testing, processing, storage, and distribution. It applies to blood establishments (organizations collecting and processing blood for transfusion) and hospital blood banks.

The National Health Service (NHS) covers the cost of blood acquisition, processing, and transfusion within its overall budget. This includes the cost of blood typing associated with the donated blood.

Competitive Landscape

Key Players

Here are some of the major key players in the UK Blood Group Typing Market:

• Grifols S.A.
• Bio-Rad Laboratories, Inc.
• Ortho Clinical Diagnostics
• Danaher Corporation
• Merck KGaA
• Quotient Limited
• Becton, Dickinson and Company
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Prestige Diagnostics